Featured Posters & Presentations
Lyfgenia
Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy.
Authors: Walters MC.
Lyfgenia
Polyclonality strongly correlates with biological outcomes and is significantly increased following improvements to the phase 1/2 HGB-206 protocol and manufacturing of LentiGlobin for sickle cell disease (scd; bb1111) gene therapy (GT).
Authors: Tisdale JF.